 Heparin, Low-Molecular-Weight
"Heparin, Low-Molecular-Weight" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism.
| Descriptor ID |
D006495
|
| MeSH Number(s) |
D09.698.373.400.300
|
| Concept/Terms |
Heparin, Low-Molecular-Weight- Heparin, Low-Molecular-Weight
- Heparin, Low Molecular Weight
- LMWH
- Low Molecular Weight Heparin
- Low-Molecular-Weight Heparin
|
Below are MeSH descriptors whose meaning is more general than "Heparin, Low-Molecular-Weight".
Below are MeSH descriptors whose meaning is more specific than "Heparin, Low-Molecular-Weight".
This graph shows the total number of publications written about "Heparin, Low-Molecular-Weight" by people in this website by year, and whether "Heparin, Low-Molecular-Weight" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 1 | 3 | | 2001 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2008 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 2 | 2 | | 2013 | 2 | 0 | 2 | | 2014 | 1 | 2 | 3 | | 2018 | 1 | 0 | 1 | | 2021 | 2 | 1 | 3 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Heparin, Low-Molecular-Weight" by people in Profiles.
-
Wang TF, Khorana AA, Agnelli G, Bloomfield D, Bonaca MP, B?ller HR, Connors JM, Goto S, Jing ZC, Kakkar AK, Khder Y, Raskob GE, Soff GA, Verhamme P, Weitz JI, Carrier M. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction. Oncologist. 2023 07 05; 28(7):555-564.
-
Buckley MS, Benanti GE, Gilbert B, Meckel J, Dzierba AL, MacLaren R. Correlation between heparin anti-Xa activity and thromboelastography in adult critically ill COVID-19 patients. Pharmacotherapy. 2023 08; 43(8):795-803.
-
Humphries B, Le?n-Garc?a M, Bates SM, Guyatt G, Eckman MH, D'Souza R, Shehata N, Jack SM, Alonso-Coello P, Xie F. Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed-methods pilot study. BMJ Evid Based Med. 2023 10; 28(5):309-319.
-
Podda M, De Simone B, Ceresoli M, Virdis F, Favi F, Wiik Larsen J, Coccolini F, Sartelli M, Pararas N, Beka SG, Bonavina L, Bova R, Pisanu A, Abu-Zidan F, Balogh Z, Chiara O, Wani I, Stahel P, Di Saverio S, Scalea T, Soreide K, Sakakushev B, Amico F, Martino C, Hecker A, de'Angelis N, Chirica M, Galante J, Kirkpatrick A, Pikoulis E, Kluger Y, Bensard D, Ansaloni L, Fraga G, Civil I, Tebala GD, Di Carlo I, Cui Y, Coimbra R, Agnoletti V, Sall I, Tan E, Picetti E, Litvin A, Damaskos D, Inaba K, Leung J, Maier R, Biffl W, Leppaniemi A, Moore E, Gurusamy K, Catena F. Follow-up strategies for patients with splenic trauma managed non-operatively: the 2022 World Society of Emergency Surgery consensus document. World J Emerg Surg. 2022 10 12; 17(1):52.
-
Modi RN, Borst JM, Kirchberg TN, Box K, Smith AM, Godat LN, Doucet JJ, Costantini TW, Berndtson AE. One size does not fit all: Sex bias in pharmacologic venous thromboembolism prophylaxis. J Trauma Acute Care Surg. 2023 01 01; 94(1):78-85.
-
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
-
Do KT, Chow LQM, Reckamp K, Sanborn RE, Burris H, Robert F, Camidge DR, Steuer CE, Strickler JH, Weise A, Specht JM, Gutierrez M, Haughney P, Hengel S, Derleth CL, Yap TA. First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors. Oncologist. 2021 11; 26(11):925-e1918.
-
Humphries B, Le?n-Garc?a M, Bates S, Guyatt G, Eckman M, D'Souza R, Shehata N, Jack S, Alonso-Coello P, Xie F. Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed methods pilot study protocol. BMJ Open. 2021 03 22; 11(3):e046021.
-
Delate T, Charlu M, Zhu S, Pai A, Clark NP, Witt DM, King JM, King JB. Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism. Thromb Res. 2020 12; 196:367-370.
-
Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, Shehab N, Mock J, Myers T, Dentali F, Crowther MA, Agarwal A, Bhatt M, Khatib R, Riva JJ, Zhang Y, Guyatt G. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 11 27; 2(22):3257-3291.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|